# A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

> **NCT07318883** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 720 (estimated)

## Conditions studied

- Squamous NSCLC

## Interventions

- **DRUG:** HLX07
- **DRUG:** HLX07 placebo
- **DRUG:** Serplulimab
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel or Nab-Paclitaxel

## Key facts

- **NCT ID:** NCT07318883
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2031-01
- **Final completion:** 2031-01
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07318883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07318883, "A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07318883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*